Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dropbox Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while Dropbox Inc trades at $33.59 (market cap $7.41B). The key difference: Dropbox Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | DBX | |
|---|---|---|
Market Cap | $5.07B | $7.41B |
Sector | Health | Technology |
52-Week High | $29.41 | $35.00 |
52-Week Low | $20.06 | $22.06 |
Enterprise Value | $4.19B | $10.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Dropbox (DBX) trades at $33.68, down 2.63% on the day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.75, exceeding expectations of $0.74, driven by core file-sync-and-share growth and AI expansion. Despite a negative shareholder equity position, operating cash flow remains strong at $952 million for 2025, supporting ongoing business investments.
The outlook is cautiously optimistic, with raised 2026 guidance signaling management confidence, but high debt levels and competitive pressures in cloud storage pose risks. Analyst sentiment is mixed, with 37.5% recommending buy, highlighting potential upside if execution continues, though investors should weigh valuation against balance sheet concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
